课题基金 / 基金详情

IMMUNOBIOLOGY OF THE HEMOPOIETIC HISTOCOMPATIBILITY

IMMUNOBIOLOGY OF THE HEMOPOIETIC HISTOCOMPATIBILITY
造血组织相容性的免疫生物学
批准号:
3181778
负责人:
ICHIRO NAKAMURA
金额:
$12.98万
依托单位国家:
美国
项目类别:
财政年份:
1986
资助国家:
美国
项目状态:
已结题
起止时间:
1986-08-01 至 1990-07-31

项目摘要

项目成果

ICHIRO NAKAMURA的其他基金

相似基金

相关文献

中文摘要
翻译
这一建议的目的是剖析鲜为人知的机制(S), 小鼠对正常和恶性造血系统的天然抵抗力 细胞,这自相矛盾地表现在F1杂交受体中 亲本嫁接(杂交抗性),由自然杀伤(NK)介导 细胞样的效应器。假定靶细胞表面的表达 结构及其被效应器识别,是免疫遗传的 由一类看似“非共显性”的基因所控制 有限多态,即HH(用于造血组织相容性) 基因。建议研究的主要目的是应用 分子遗传学技术研究杂交种的遗传基础 抗性由一个HH基因控制,即HH-1,它映射到 17号染色体H-2D区。两个可选的假设可能 解释“非共显性”将主要由DNA介导的基因来检验 转移;非共显性表达的顺式作用机制是 如果HH-1-表型通过以下方式转换为HH-1+表型,则支持 用小鼠HH-1+株DNA转染HH-1-细胞 非共显性的反式作用遗传机制将被牵连在以下情况 HH-1的DNA分子转移抑制了HH-1的表达 培养成HH-1+细胞。用这种方法,H-2D区基因 编码或调节HH-1控制结构的表达可以是 被确认和隔离。最终,这些细胞表面的性质 靶结构及其在正常和异常中的表达和功能 (白血病)造血和NK样细胞的生理作用 认识到这种结构,可以被定义。因此,这项研究应该 帮助解开一个重要的,可能是监管的主要职能 一类淋巴细胞的组织相容性复合体和真实功能, 即NK细胞。
英文摘要
The objective of this proposal is to dissect the little known mechanism(s), underlying murine natural resistance to normal and malignant hemopoietic cells, which paradoxically manifests itself in F1 hybrid recipients of parental grafts (hybrid resistance) and is mediated by natural killer (NK) cell-like effectors. The expression of the putative target cell surface structure and its recognition by the effectors, are immunogenetically specific and controlled by a class of seemingly "noncodominant" genes of limited polymorphism, i.e., the Hh (for hemopoietic histocompatibility) genes. It is the primary purpose of the proposed study to apply the techniques of molecular genetics to understand the genetic basis of hybrid resistance controlled by one of the Hh loci, the Hh-1, that maps to the H-2D region of the 17th chromosome. Two alternative hypotheses that may explain the "noncodominance" will be tested primarily by DNA-mediated gene transfer; a cis-acting mechanism of noncodominant expression would be supported if a Hh-1- phenotype is converted to a Hh-1+ phenotype by transfecting a Hh-1- cell with DNA from Hh-1+ strain of mouse, whereas a trans-acting genetic mechanism of noncodominance would be implicated if Hh-1 expression is suppressed by transfer of a DNA molecule from a Hh-1- strain into a Hh-1+ cell. With this approach, the H-2D region gene encoding or regulating the expression of Hh-1-controlled structures can be identified and isolated. Ultimately, the nature of these cell surface target structures, their expression and function in normal and abnormal (leukemic) hemopoiesis, and a physiological role of Nk-like cells recognizing such structures, may be defined. This study, therefore, should help unravel an important, possibly regulatory, function of the major histocompatibility complex and true functions of a class of lymphoid cells, i.e., the NK cells.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Hemopoietic histocompatibility (Hh-1) phenotype and the regulation of its expression.
造血组织相容性(Hh-1)表型及其表达的调节。
DOI: 10.1007/bf00189521
发表时间: 1992
期刊: Immunogenetics
影响因子: 3.2
作者: [Kaminsky,SG, Yoshida,MA, Milisauskas,VK, Nakamura,I]
通讯作者: Nakamura,I
The B144-H-2Db interval and the location of a mouse homologue of the human D6S81E locus.
B144-H-2Db 间隔和人类 D6S81E 基因座的小鼠同源物的位置。
DOI: 10.1007/bf02114974
发表时间: 1990
期刊: Immunogenetics
影响因子: 3.2
作者: [Wroblewski,JM, Kaminsky,SG, Milisauskas,VK, Pittman,AM, Chaplin,DD, Spies,T, Nakamura,I]
通讯作者: Nakamura,I
Acute rejection of allogeneic hemopoietic progenitors by genetically resistant mice.
遗传抗性小鼠对同种异体造血祖细胞的急性排斥。
DOI: 10.1002/eji.1830190702
发表时间: 1989
期刊: European journal of immunology
影响因子: 5.4
作者: [Shimamura,K, Kaminsky,SG, Nakamura,I]
通讯作者: Nakamura,I
Class I H-2Db determinants are not involved in hybrid resistance to parental H-2b/Hh-1b bone marrow allograft.
I 类 H-2Db 决定簇不参与对亲本 H-2b/Hh-1b 骨髓同种异体移植物的杂种抗性。
DOI: 10.1002/eji.1830170722
发表时间: 1987
期刊: European journal of immunology
影响因子: 5.4
作者: [Milisauskas,VK, Kaminsky,SG, Nakamura,I]
通讯作者: Nakamura,I
GENETIC ANALYSIS OF HEMOPOIETIC HISTOCOMPATIBILITY
GENETIC ANALYSIS OF HEMOPOIETIC HISTOCOMPATIBILITY
GENETIC ANALYSIS OF HEMOPOIETIC HISTOCOMPATIBILITY
IMMUNOBIOLOGY OF THE HEMOPOIETIC HISTOCOMPATIBILITY
海外基金